ENDOCYTE – Small and Powerful Targeted Therapy!

Date: 2015-07

Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s attention when Merck paid total $1b + 50/50 profit sharing in US + royalty payment on ex. US to its key drug Vintafolide. ECYT expects a response to the 120-day questions submission by mid year based on which Merck will make a no/go decision on the MAA. While the data looks promising in FR+ve pts for PFS, no OS benefit has been observed in PhII. The PhIII trial is more stringent and the odds of success are high. Attractive technology platform- SMDC has broad application and offers advantage over antibody drug conjugate technologies. ECYT has a robust cash position and presents..…..For more detail, please read our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample